Boehringer and Zealand want to outperform Novo and are comparing their obesity treatment to semaglutid
Boehringer Ingelheim and Zealand Pharma are collaborating to develop an obesity treatment, which they are comparing to semaglutid in a new phase II study. The treatment is a potential future winner, says Zealand Pharma.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
Boehringer Ingelheim and Zealand Pharma have high expectations for their obesity treatment, BI 456906.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
